Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …

Abstract Background & Aims Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic
steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of …

Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general
population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to …

Background Pemafibrate is a novel, selective peroxisome proliferator‐activated receptor α
modulator (SPPARMα). In mice, Pemafibrate improved the histological features of non …

Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for
diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) is primarily caused by abnormal lipid metabolism
and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic …

Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) have become significant global health concerns. In the present study, we aimed to …

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from
simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no …

Introduction: Nonalcoholic fatty liver disease (NAFLD) encompasses a progressive disease
phenotype starting from simple steatosis, which can progress to nonalcoholic steatohepatitis …